Intec Pharma Ltd Company Profile (NASDAQ:NTEC)

About Intec Pharma Ltd (NASDAQ:NTEC)

Intec Pharma Ltd logoIntec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson's disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NTEC
  • CUSIP: N/A
  • Web:
  • Market Cap: $74.18 million
  • Outstanding Shares: 13,737,000
Average Prices:
  • 50 Day Moving Avg: $5.38
  • 200 Day Moving Avg: $5.14
  • 52 Week Range: $3.54 - $6.36
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.35
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.98 per share
  • Price / Book: 2.73
  • EBIDTA: ($13,150,000.00)
  • Current Ratio: 20.09%
  • Quick Ratio: 20.09%
  • Average Volume: 9,410 shs.
  • Beta: 1.75
  • Short Ratio: 0.72

Frequently Asked Questions for Intec Pharma Ltd (NASDAQ:NTEC)

What is Intec Pharma Ltd's stock symbol?

Intec Pharma Ltd trades on the NASDAQ under the ticker symbol "NTEC."

How were Intec Pharma Ltd's earnings last quarter?

Intec Pharma Ltd (NASDAQ:NTEC) released its earnings results on Thursday, November, 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.09. View Intec Pharma Ltd's Earnings History.

Where is Intec Pharma Ltd's stock going? Where will Intec Pharma Ltd's stock price be in 2017?

1 analysts have issued twelve-month price objectives for Intec Pharma Ltd's stock. Their predictions range from $9.00 to $9.00. On average, they expect Intec Pharma Ltd's stock price to reach $9.00 in the next year. View Analyst Ratings for Intec Pharma Ltd.

What are analysts saying about Intec Pharma Ltd stock?

Here are some recent quotes from research analysts about Intec Pharma Ltd stock:

  • 1. According to Zacks Investment Research, "Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson's disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. " (5/24/2017)
  • 2. Maxim Group analysts commented, " As Intec initiates phase I trials of CBD/THC using the accordion delivery system, it opens up a new option for shareholders. The company extends the potential therapeutic utility of its proprietary delivery system beyond Parkinson's disease and insomnia. Cannabinoid-based therapeutics is a large, growing market, and as such, we look forward to any positive progress in this program which could be another value driver for the company." (3/24/2017)

Who are some of Intec Pharma Ltd's key competitors?

When did Intec Pharma Ltd IPO?

(NTEC) raised $30 million in an initial public offering (IPO) on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO.

Who owns Intec Pharma Ltd stock?

Intec Pharma Ltd's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (3.75%). View Institutional Ownership Trends for Intec Pharma Ltd.

Who bought Intec Pharma Ltd stock? Who is buying Intec Pharma Ltd stock?

Intec Pharma Ltd's stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for Intec Pharma Ltd.

How do I buy Intec Pharma Ltd stock?

Shares of Intec Pharma Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Intec Pharma Ltd stock cost?

One share of Intec Pharma Ltd stock can currently be purchased for approximately $5.40.

Analyst Ratings

Consensus Ratings for Intec Pharma Ltd (NASDAQ:NTEC) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.00 (66.67% upside)

Analysts' Ratings History for Intec Pharma Ltd (NASDAQ:NTEC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/24/2017Maxim GroupReiterated RatingBuy$9.00LowView Rating Details
12/16/2015Roth CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for Intec Pharma Ltd (NASDAQ:NTEC)
Earnings by Quarter for Intec Pharma Ltd (NASDAQ:NTEC)
Earnings History by Quarter for Intec Pharma Ltd (NASDAQ:NTEC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/5/2015Q3 2015($0.07)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Intec Pharma Ltd (NASDAQ:NTEC)
2017 EPS Consensus Estimate: ($1.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.31)($0.31)($0.31)
Q2 20171($0.31)($0.31)($0.31)
Q3 20171($0.31)($0.31)($0.31)
Q4 20171($0.31)($0.31)($0.31)
(Data provided by Zacks Investment Research)


Dividend History for Intec Pharma Ltd (NASDAQ:NTEC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Intec Pharma Ltd (NASDAQ:NTEC)
No insider trades for this company have been tracked by


Headline Trends for Intec Pharma Ltd (NASDAQ:NTEC)
Latest Headlines for Intec Pharma Ltd (NASDAQ:NTEC)
DateHeadline logoIntec Pharma (NTEC) Granted U.S. Patent for Accordion Pill - May 24 at 7:06 PM logoIntec Pharma Granted U.S. Patent for Accordion Pill™ Comprising Levodopa for Improved Treatment of Parkinson's Diseases Symptoms - May 24 at 10:24 AM logoIntec Pharma Ltd (NTEC) Expected to Announce Earnings of -$0.31 Per Share - May 12 at 7:40 AM logoIntec Pharma (NTEC) Given Media Impact Rating of 0.12 - May 5 at 10:34 PM logoIntec Pharma Announces CEO Change - May 3 at 8:03 PM logoIntec Pharma (NTEC) Given Coverage Optimism Rating of 0.26 - April 28 at 12:26 AM logoBRIEF-Intech Biopharm signs agreement with TWi Pharmaceuticals on joint development of asthma drugs - April 26 at 6:20 PM logoIntec Pharma (NTEC) Getting Favorable Media Coverage, Report Finds - April 24 at 3:20 PM logoIntec Pharma (NTEC) Earns Daily Media Sentiment Score of 0.50 - April 17 at 12:56 PM logoIntec Pharma (NTEC) Earning Positive News Coverage, Analysis Shows - April 13 at 7:46 PM logoIntec Pharma Appoints U.S. Life Sciences Executive Jeffrey A. Meckler to its Board of Directors as Vice Chairman - April 9 at 9:41 AM logoIntec Pharma Ltd (NTEC) Short Interest Up 1,208.7% in March - April 7 at 8:00 PM logoBRIEF-Intec Pharma files for resale of 2.1 mln ordinary shares - April 7 at 11:33 AM logoIntec Pharma Reports 2016 Fourth Quarter and Full Year Financial Results - April 7 at 11:33 AM logo Intec Pharma Ltd (NTEC) Given Consensus Rating of "Strong Buy" by Analysts - April 6 at 8:04 AM logoBRIEF-Intec Pharma provides update on phase III accordance study of the accordion pill - March 29 at 9:24 AM logoIntec Pharma Provides Update on Phase III ACCORDANCE Study of the Accordion Pill Carbidopa/Levodopa in Parkinson's Disease Patients - March 29 at 9:24 AM logoIntec Pharma Ltd (NTEC) Raised to Buy at Zacks Investment Research - March 24 at 3:02 PM logoIntec Pharma Ltd (NTEC) Rating Reiterated by Maxim Group - March 24 at 11:13 AM logoIntec Pharma Ltd Forecasted to Earn FY2016 Earnings of ($1.23) Per Share (NTEC) - March 24 at 8:05 AM logoBRIEF-Intec Pharma initiates Phase I trial of accordion pill for cannabinoid therapies - March 22 at 11:57 PM logoIntec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies - March 22 at 9:13 AM logoIntec Pharma to Participate in the Oppenheimer 27th Annual Healthcare Conference - March 17 at 7:03 PM logo8:01 am Intec Pharma enters into agreements with several investors for the private placement of 2,289,638 ordinary shares of the Co, at a price of $4.40/share - March 10 at 8:40 PM logoIntec Pharma to Participate in the 29th Annual Roth Conference - March 10 at 8:40 PM logoBRIEF-Intec Pharma announces $10 million private placement - March 10 at 9:24 AM logoIntec Pharma Announces $10 Million Private Placement - March 10 at 9:24 AM logoIntec Pharma (NTEC) Enters Agreement with Michael J. Fox Foundation to Support Trial Recruitment - November 30 at 7:02 PM logoIntec Pharma Enters into Agreement with the Michael J. Fox Foundation Around Its Phase III Trial Recruitment - November 29 at 2:27 PM logoInsomnia Pipeline Landscape and Therapeutics Development Market Review H2 2016 - November 17 at 6:11 PM logoIntec Pharma to Sponsor Investigator Meeting for Pivotal Phase III Study of Accordion Pill Carbidopa/Levodopa in Advanced Parkinson's Disease Patients - November 12 at 9:05 AM logoIntec Pharma to Sponsor Investigator Meeting for Pivotal Phase III Study of Accordion Pill Carbidopa/Levodopa … - November 9 at 8:57 AM logoIntec Pharma cuts sample size in late-stage study of lead product candidate by almost 30%; shares up 11% - November 8 at 9:50 AM logoBRIEF-Intec Pharma makes amendment to advanced parkinson's patient's study - November 7 at 10:21 AM logoIntec Pharma Announces Protocol Amendment to Phase III Study of Accordion Pill Carbidopa/Levodopa in Advanced Parkinson's Disease Patients - November 7 at 10:21 AM logoIntec Pharma Granted Chinese Patent for Accordion Pill TM Carbidopa / Levodopa - October 31 at 1:16 PM logoForm 6-K Intec Pharma Ltd. For: Oct 07 - October 7 at 11:35 AM logoIntec Pharma to Participate in Upcoming September Conferences - September 7 at 6:38 PM logoIntec Pharma Granted European Patent for Accordion Pill™–Carbidopa / Levodopa - September 7 at 10:03 AM logoIntec Pharma Posts Wider Loss In Q2 - Quick Facts - September 2 at 11:20 AM logoIntec Pharma Reports First Half 2016 Financial Results - September 2 at 11:20 AM logoIntec Pharma Names Nir Sassi CFO, Effective Aug. 1, Succeeding Oren Mohar - June 3 at 9:23 AM logoIntec Pharma Nominates John Kozarich As Chairman Of Board - Quick Facts - May 16 at 1:09 PM logoCYTR Awaits Data In June, GILD Gets FDA Nod, PGNX Will Have To Wait - April 5 at 11:54 AM logoINTEC PHARMA LTD. Financials - March 17 at 1:04 PM logoMr. Zvika Joseph to Step Down as Chairman of the Board of Directors - March 17 at 10:30 AM logoIntec Pharma Reports 2015 Fourth Quarter and Full-Year Financial Results - March 14 at 7:45 AM logoIntec Pharma Ltd. Announces Availability of Its Annual Report on Form 20-F Through Its Website - March 14 at 7:30 AM logoIntec Pharma Ltd.: Notice of Special General Meeting of Shareholders - March 14 at 7:15 AM logo8:11 am Intec Pharma completes Phase 1 clinical trial with third pipeline product - March 10 at 8:11 AM



Intec Pharma Ltd (NTEC) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff